Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Patients with Raynaud's phenomenon suffer from painful attacks triggered by stress or cold
causing acute lowering of blood flow through the digits. In this trial the safety and
efficacy as well as the effect of one dose of the sGC stimulator Riociguat on digital blood
flow will be measured during a cold exposure test in patients suffering from Raynaud's
phenomenon. Measurements of two periods will be compared: in one period the patient will be
given active drug and in the other period a placebo.